Evidence map›Paper›PMID 32049988›Full record

Trial reportPloS one2020

Allocating colorectal cancer patients to different risk categories by using a five-biomarker mRNA combination in lymph node analysis.

Lina Olsson, Marie-Louise Hammarström, Anne Israelsson, Gudrun Lindmark, Sten Hammarström

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. mRNA-based therapeutic strategies for cancer treatment.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lina OlssonDepartment of Clinical Microbiology, Section of Infection and Immunology, Umeå University, Umeå, Sweden.
Marie-Louise HammarströmDepartment of Clinical Microbiology, Section of Infection and Immunology, Umeå University, Umeå, Sweden.ORCID 0000-0001-6182-4423
Anne IsraelssonDepartment of Clinical Microbiology, Section of Infection and Immunology, Umeå University, Umeå, Sweden.
Gudrun LindmarkDepartment of Clinical Sciences, Lund University, Helsingborg, Sweden.
Sten HammarströmDepartment of Clinical Microbiology, Section of Infection and Immunology, Umeå University, Umeå, Sweden.
Umeå University · SELund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsCurative surgery saves ≈50% of all patients with colorectal cancer (CRC) while remaining patients have synchronous or will develop metachronous metastases. Presently, the single most important prognostic factor is histopathological detection of disseminated tumor cells in regional lymph nodes. However, the routine method has several limitations. The aim was to identify biomarker mRNAs that could be combined in a formula that would allow better prediction of patients' survival after surgery.

methodsScreening for biomarker mRNAs overexpressed in CRC was performed by genome-wide hybridization bead array, with verification by qRT-PCR. Specific qRT-PCR assays with copy standards were developed for 5 selected genes and mRNA expression levels determined in lymph nodes from 174 CRC patients (517 nodes) and 24 control patients (118 nodes). Prognostic value of biomarker mRNAs was estimated. A cut-off was set using univariate Cox regression analysis and used for calculation of differences between patient groups in disease-free survival 12 years after surgery (Kaplan-Meier survival model) and risk for recurrent disease (Cox's regression analysis). A formula was constructed for evaluation of the prognostic value of the biomarkers in combination.

resultsTwo new biomarkers, SLC35D3 and POSTN with prognostic value were identified. SLC35D3 was expressed in the epithelium derived tumor cells and POSTN in fibroblasts. Combined with CEACAM5, KLK6 and MUC2 they could be used to identify risk groups. A formula was constructed using CEACAM5 as denominator for KLK6, SLC35D3 and MUC2 and 18S rRNA as denominator for POSTN. The formula yielded 5 categories (-1, 0, 1, 2, 3). Categories (-1 and 0) had good prognosis, categories (1 and 2) relatively poor prognosis and category (3) very poor prognosis.

conclusionLymph node analysis using 5 selected biomarker mRNAs and 18S rRNA in combination allowed allocation of CRC patients to different risk categories with respect to recurrent disease.

Indexed as

Biomarkers, TumorColorectal NeoplasmsLymph NodesRNA, NeoplasmAgedAged, 80 and overCaco-2 CellsFemaleGenome-Wide Association StudyHumansJurkat CellsMaleMiddle AgedNeoplasm ProteinsRisk AssessmentRNA, MessengerBiomarkers, TumorNeoplasm ProteinsRNA, MessengerRNA, Neoplasm

Identifiers

PMID32049988
PMCPMC7015415
OpenAlexW3005684952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.